VICTORIA, Oct. 2, 2018
VICTORIA, Oct. 2, 2018 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) announced the addition of in-house and custom phage libraries to their growing service offeringsthrough their recent expansion in Europe. Through construction and screening of scFv and VHH phage display libraries, ImmunoPrecise is able to generate monoclonal antibodies, in a diverse range of animal species, against complex protein structures.
The Company offers access to proprietary in-house human and llama VHH phage libraries, applicable for non-immunogenic and toxic targets, the construction of custom immune libraries prepared from a diverse range of animal species, and synthetic phage libraries generated for state-of-the-art humanization and affinity maturation procedures to optimize lead candidates for clinical trials. Access to their royalty-free human scFv and llama VHH repertoires, along with expertise in protein and antibody engineering, positions the Company as a desirable provider for bispecific antibody development.
A Powerful Method for Therapeutic Antibody Development
Antibody phage display uses genetically engineered bacteriophage to express a single antibody fragment sequence on their outer surface, allowing isolation of the antibody-bound phage with the required characteristics by selection on the target.
Through phage display, ImmunoPrecise is able to offer another avenue of therapeutic antibody discovery; positioning them as a full-service CRO offering the full continuum of antibody discovery, manufacturing and engineering, to deliver a broad and diverse panel of antibodies for therapeutic campaigns.
Diversity - Specificity - Stability
- Access to naïve and disease human, and naïve llama immune repertoires from in-house libraries
- Custom immune libraries prepared from blood, spleen, lymph nodes, and bone marrow of a diverse range of immunized animals
- Llama VHH antibodies offer high stability and small size
- Allows high specificity selection to obtain a large diverse, highly specific antibody repertoire for full characterization
- Unlimited re-screening of the library repertoires
- Library-derived sequences for bispecific antibody development in multiple formats